Achieving a major molecular response (
MMR) is the goal of imatinib therapy for chronic myeloid leukemia. However, the association between gender, transcript type, and age with BCR‐ ABL MMRis not well understood and often controversial. Methods
We retrospectively analyzed 166 patients who have been treated with imatinib for up to 10 yr.
Men had a lower
MMRrate than women (63.3% vs. 81.6%, P= 0.006) and a shorter time to relapse (median 354 vs. 675 d, P= 0.049), while patients with b3a2 or with both b3a2 and b2a2 break point transcripts had higher MMRrate than those with b2a2 (81.8%, 77.1% vs. 60.7%, P= 0.023 for b3a2 vs. b2a2, P= 0.043 for both vs. b2a2). A striking difference was found between men with b2a2 and women with both b2a2 and b3a2 in terms of MMRrate (43.8% vs. 88.9%), MMRrate within 6 months (7.1% vs. 62.5%) and the time to MMR(median d 493 vs. 159, P= 0.036). Conclusions
Both gender and
transcript, but not age, were significantly associated with the molecular response. Men with b2a2 represent a less favorable group in their response to imatinib treatment and may need alternative therapy regimen and closer monitoring. BCR‐ ABL